ORKA · Oruka Therapeutics, Inc.
$92.38
+0.80% last session
End-of-day data · close of 2026-09-11
Market cap
$6B
Enterprise value
$5B
Trailing P/E
—
Forward P/E
-32.0
Dividend yield
—
Beta
-0.21
Avg volume
1M
Employees
0K
Daily Change %
0.80%
5 Days Change
-1.09%
10 Days Change
-1.21%
30 Days Change
-12.59%
60 Days Change
5.43%
Month to Day Change
-0.66%
Year to Day Change
201.88%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ORKA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-03
Latest call per bank · past 12 months
UBS
Buy$130
+41.8% vs priceBarclays
Overweight$160
+74.6% vs priceJefferies
Buy$45.00
-50.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-03 | HC Wainwright & Co. | Reiterates | Buy | $120 |
| 2026-08-11 | Guggenheim | Reiterates | Buy | $200 |
| 2026-08-11 | Wedbush | Reiterates | Outperform | $165 |
| 2026-08-11 | BTIG | Reiterates | Buy | $151 |
| 2026-08-03 | HC Wainwright & Co. | Reiterates | Buy | $120 |
| 2026-07-13 | BTIG | Reiterates | Buy | $151 |
| 2026-07-01 | UBS | Maintains | Buy | $100 → $130 |
| 2026-06-23 | HC Wainwright & Co. | Reiterates | Buy | $120 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 43 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 3.1% below the 50-day MA ($95.31).
- Price vs 200-day MA: Trading 55.3% above the 200-day MA ($59.48).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.16) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($14.90) and high ($113.08).
ORKA Price Chart
Loading chart for ORKA…
Fundamentals
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.